Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis

Exclusion Criteria

• •Patient has a concurrent medical/arthritic disease that could confound or interfere with evaluation of efficacy
• •Patient is legally incompetent (e.g., a minor or mentally incapacitated), or has active psychosis, or significant emotional problems at the time of the study which in the view of the investigator are sufficient to interfere with the conduct of the study
• •Patient has a history of gastric or biliary surgery (including gastric bypass surgery), or small intestine surgery that causes clinical malabsorption
• •Patient is allergic to, or has a history of a significant clinical or laboratory adverse experience associated with etoricoxib or celecoxib or any of their constituents
• •Patient is allergic to acetaminophen/paracetamol, or has hypersensitivity (e.g., bronchoconstriction in association with nasal polyps) to aspirin or NSAIDs
• •Patient has an estimated glomerular filtration rate is less than or equal to 30 ml/min
• •Patient has Class II-IV congestive heart failure
• •Patient has established ischemic heart disease, cerebrovascular disease, or peripheral vascular disease
• •Patient has uncontrolled hypertension with an diastolic exclusionary limit of \> 90 mm Hg and a systolic exclusionary limit of \> 140 mm Hg
• •Patient has moderate or severe hepatic insufficiency defined as Child Pugh score \> 6
• •Patient has a history of neoplastic disease
• •Patient has a history of any illness, which in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient
• •Patient is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last 5 years) of drug or alcohol abuse or dependence
• •Patients considered morbidly obese with a body mass index (BMI) ≥ 35 kg/m\^2
• •Patient has new use (within 2 weeks of Visit 1 and during the entire duration of the study and follow-up period) of physical medicine modalities involving the study joint, including but not limited to: physical therapy, chiropractic interventions, acupuncture, Transcutaneous Electrical Nerve Stimulator (TENS), and ultrasound
• •Patient is expected to undergo surgery involving the study joint during the course of the study
• •Patients taking oral contraceptives
• •Patients using intra-articular steroids or hyaluronic acid injections to the study knee or other immunosuppressant medication within 3 months of Visit 1
• •Patients using intravenous, intramuscular, or oral corticosteroids, intra-articular steroids or hyaluronic acid injections to any joint other than the study joint within 1 month of Visit 1
• •Patients using topical or systemic analgesic medications within 3 days of Visit 1 and throughout the duration of the study
• •Patients using non-study NSAID or cyclooxygenase 2 (COX-2) specific inhibitor during the study treatment period, with the exception of low-dose aspirin (≤ 325 mg/day)
• •Patients receiving a Chinese traditional arthritis treatment within 1 week of Visit 1
• •Patients with clinically significant abnormalities on Visit 1 clinical examination or laboratory safety tests. Serum transaminases should be ≤ 150% of the upper limit of normal
• •Patients currently participating in or has participated in a study with an
• •investigational drug or device within 4 weeks of signing informed consent
• •Patients with an active peptic ulcer or a history of inflammatory bowel disease
• •Patients with a personal or family history of an inherited or acquired bleeding
• •Patients that are pregnant or breast-feeding, or expecting to conceive within the projected duration of the study